The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma
WithdrawnPhase 3NCT03255330
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Study of the effect of gabapentin used as a preemptive to the emergence and development chronic neuropathic pain in patients after spinal cord trauma
Study details
- Official title
- The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma
- Conditions
- Chronic Pain Due to Trauma
- Spinal Cord Injuries
- Interventions
- Drug: Gabapentin
- Drug: Metamizol
- Drug: Tramadol
- Sponsor
- Masaryk University
- Start date
- 2017-10
- Primary completion
- 2020-02
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Czechia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Men and women, age 18 - 65 years 2. Signed written informed consent 3. Patients after complete/non-complete spinal lesion, after surgery 4. Patients with spinal cord trauma caused mechanically demanding (due a injury of a bone fragment, a disk, a translation spinal canal) 5. Patient willing and able to comply with the study protocol 6. Male and females with a highly effective method of birth control plus an additional barrier method Exclusion Criteria: 1. Patients with spinal cord lesion ischemic etiology 2. Pregnant women, nursing or childbearing age with a positive pregnancy test input 3. Patients unable or unwilling to comply with the study protocol 4. Acute pancreatitis in 1 year from the start of the study 5. Chronic pancreatitis in the case history 6. Active or uncontrolled infectious diseases 7. Hypersensitivity to any component of the investigational product 8. Active autoimmune disease 9. Serious neurological disease with the incidence chronic neuropathic pain
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03255330